Dr. Rajesh Behl is a hematologist in Berkeley, California. He is affiliated with multiple hospitals in the area, including Alta Bates Summit Medical Center and Alta Bates Summit Medical Center - Summit Campus. He received his medical degree from Maulana Azad Medical College and has been in practice for 21 years. He is one of 13 doctors at Alta Bates Summit Medical Center and one of 13 at Alta Bates Summit Medical Center - Summit Campus who specialize in Hematology.
Education & Medical Training
University of Minnesota
Residency, Internal Medicine, 1995–1998
Washington University
Fellowship, Hematology/Oncology, 1998–2001
Maulana Azad Medical College
Class of 1993
Certifications & Licensure
American Board of Internal Medicine
Certified in Internal Medicine
American Board of Internal Medicine
Certified in Medical Oncology
CA State Medical License
Active through 2015
Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
BehlR@sutterhealth.org
Related Clinical Trials
Connect
Connect® MDS/AML Disease Registry
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Myelofibrosis (INCB 50465-304)
A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Myelofibrosis (INCB 50465-313)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibros
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Relapesed/Refractory (MAGNIFY)
Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
Investigator: Rajesh Behl M.D.
Status: Active, Not Recruiting